Tissue Plasminogen Activator connected with Roche dominance expands market
Tissue Plasminogen Activator |
Market Overview:
Tissue
plasminogen activator (tPA) is a protein involved in the breakdown of blood
clots. tPA is produced naturally in cells that line arteries and veins, and it
enters the bloodstream in response to injury in order to dissolve clots and
prevent larger clots from forming. Recombinant tPA is a manufactured version of
tPA produced through biotechnology that is used clinically in the treatment of
ischemic strokes. By allowing faster restoration of blood flow, tPA has been
shown to significantly improve outcomes for stroke patients when administered
within 4.5 hours of symptom onset. The need for swift treatment of ischemic
strokes and advantages of recombinant tPA over other thrombolytic agents like
increased efficiency and specificity for clots drive demand in the tPA market.
Market key trends:
One of the key trends in the global tPA market is the dominance of Roche's
brand Activase. Activase accounted for over 90% of the tPA market share in
2022. The drug has been the gold standard treatment for ischemic strokes for
over 30 years. Roche holds valuable patents protecting Activase which is a
major barrier for other manufacturers to enter the market. The expiry of these
patents after 2023 may see increased competition from biosimilar tPAs. However,
Roche's strong brand recognition and reputation are likely to maintain its
market leadership position over the forecast period.
Porter’s
Analysis Content
Threat of
new entrants: The Tissue
Plasminogen Activator Market Size has moderate threat of new entrants
due to high research costs involved in the development of new drugs and the
requirement of strong distribution networks.
Bargaining power of buyers: The bargaining power of buyers is moderate as
tissue plasminogen activator is a biological drug without substitutes for
treating stroke and acute myocardial infarction.
Bargaining power of suppliers: A few major pharmaceutical companies dominate
the supply market. Hence, the bargaining power of suppliers is high in this
market.
Threat of new substitutes: Currently, there are no appropriate substitutes
available for tissue plasminogen activators. Hence, the threat from substitutes
is low.
Competitive rivalry: The tissue plasminogen activator market witnesses high
competitive rivalry amongst major players.
Key Takeaways
The global tissue plasminogen activator market is expected to witness high
growth, exhibiting CAGR of 5.2% over
the forecast period 2023-2030, due
to increasing incidences of cardiac diseases and strokes. The market was valued
at US$ 2.58 Bn in 2023.
Regionally, North America dominated the global tissue plasminogen activator
market in 2023 due to rising prevalence of cardiovascular diseases and adoption
of tissue plasminogen activator therapy. However, Asia Pacific is expected to
exhibit the fastest growth over the forecast period owing to the large patient
pool and improving healthcare infrastructure in developing countries of the
region.
Key players operating in the tissue plasminogen activator market are F. Hoffmann-La
Roche AG, Boehringer Ingelheim GmbH, CHIESI Farmaceutici S.p.A., Gennova
Biopharmaceuticals Ltd, Abbott Laboratories, and Reliance Life Sciences. Major
players are focusing on new product launches and strategic collaborations to
gain higher market share.
Read More:
https://www.dailyprbulletin.com/tissue-plasminogen-activator-market-growth-demand-and-siz/
Comments
Post a Comment